| Chimeric antigen receptor T cells for sustained remissions in leukemia SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ... New England Journal of Medicine 371 (16), 1507-1517, 2014 | 6121 | 2014 |
| Chimeric antigen receptor–modified T cells for acute lymphoid leukemia SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ... New England Journal of Medicine 368 (16), 1509-1518, 2013 | 4284 | 2013 |
| Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ... Cancer discovery 6 (6), 664-679, 2016 | 1089 | 2016 |
| Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, ... Blood, The Journal of the American Society of Hematology 121 (26), 5154-5157, 2013 | 703 | 2013 |
| Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase … AS Gamis, TA Alonzo, S Meshinchi, L Sung, RB Gerbing, SC Raimondi, ... Journal of Clinical Oncology 32 (27), 3021-3032, 2014 | 483 | 2014 |
| Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury JM Marzec, JD Christie, SP Reddy, AE Jedlicka, H Vuong, PN Lanken, ... The FASEB Journal 21 (9), 2237-2246, 2007 | 420 | 2007 |
| Collaborative efforts driving progress in pediatric acute myeloid leukemia CM Zwaan, EA Kolb, D Reinhardt, J Abrahamsson, S Adachi, R Aplenc, ... Journal of clinical oncology 33 (27), 2949-2962, 2015 | 413 | 2015 |
| Low-dose, high-frequency CPR training improves skill retention of in-hospital pediatric providers RM Sutton, D Niles, PA Meaney, R Aplenc, B French, BS Abella, ... Pediatrics 128 (1), e145-e151, 2011 | 317 | 2011 |
| Genetic variants associated with cancer therapy–induced cardiomyopathy P Garcia-Pavia, Y Kim, MA Restrepo-Cordoba, IG Lunde, H Wakimoto, ... Circulation 140 (1), 31-41, 2019 | 296 | 2019 |
| Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant … N Bunin, R Aplenc, N Kamani, K Shaw, A Cnaan, S Simms Bone marrow transplantation 32 (6), 543-548, 2003 | 252 | 2003 |
| Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, ... Blood, The Journal of the American Society of Hematology 131 (9), 995-999, 2018 | 220 | 2018 |
| Epidemiology of childhood acute myeloid leukemia SE Puumala, JA Ross, R Aplenc, LG Spector Pediatric blood & cancer 60 (5), 728-733, 2013 | 216 | 2013 |
| Nucleotide Substitution in the Ectodomain of TRAIL Receptor DR4 Is Associated with Lung Cancer and Head and Neck Cancer MJ Fisher, AK Virmani, L Wu, R Aplenc, JC Harper, SM Powell, ... Clinical cancer research 7 (6), 1688-1697, 2001 | 215 | 2001 |
| Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia R Aplenc, J Thompson, P Han, M La, H Zhao, B Lange, T Rebbeck Cancer research 65 (6), 2482-2487, 2005 | 202 | 2005 |
| Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia RJ Arceci, J Sande, B Lange, K Shannon, J Franklin, R Hutchinson, ... Blood 106 (4), 1183-1188, 2005 | 192 | 2005 |
| Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. SL Maude, DT Teachey, SR Rheingold, PA Shaw, R Aplenc, DM Barrett, ... Journal of Clinical Oncology 34 (15_suppl), 3011-3011, 2016 | 180 | 2016 |
| Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial S Kadauke, RM Myers, Y Li, R Aplenc, D Baniewicz, DM Barrett, ... Journal of Clinical Oncology 39 (8), 920-930, 2021 | 173 | 2021 |
| Durable remissions in children with relapsed/refractory all treated with t cells engineered with a CD19-targeted chimeric antigen receptor (CTL019) SA Grupp, SL Maude, PA Shaw, R Aplenc, DM Barrett, C Callahan, ... Blood 126 (23), 681, 2015 | 167 | 2015 |
| CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531 JK Lamba, L Chauhan, M Shin, MR Loken, JA Pollard, YC Wang, RE Ries, ... Journal of Clinical Oncology 35 (23), 2674-2682, 2017 | 153 | 2017 |
| CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer C Zeigler-Johnson, T Friebel, AH Walker, Y Wang, E Spangler, ... Cancer research 64 (22), 8461-8467, 2004 | 153 | 2004 |
